Sareum Holdings plc (LON:SAR – Get Free Report)’s share price dropped 11.1% on Tuesday . The company traded as low as GBX 40 ($0.51) and last traded at GBX 40 ($0.51). Approximately 670,878 shares changed hands during mid-day trading, a decline of 33% from the average daily volume of 1,000,678 shares. The stock had previously closed at GBX 45 ($0.57).
Sareum Trading Down 10.8 %
The company has a market capitalization of £43.31 million, a price-to-earnings ratio of -750.00 and a beta of -1.03. The company has a fifty day moving average of GBX 35.21 and a 200-day moving average of GBX 36.63.
About Sareum
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor that is in a Phase 1a clinical trials for the treatment of autoimmune diseases.
Read More
- Five stocks we like better than Sareum
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Investing in Commodities: What Are They? How to Invest in Them
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- High Flyers: 3 Natural Gas Stocks for March 2022
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Sareum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sareum and related companies with MarketBeat.com's FREE daily email newsletter.
